Prolonging survival in metastatic prostate cancer: the case for adrenal androgens: overview and summary of therapeutic controversies in prostatic cancer.
Abstract
J Geller; Prolonging survival in metastatic prostate cancer: the case for adrenal androgens--overview and summary of therapeutic controversies in prostatic canc
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
Despite surgical or chemical castration, very low levels of androgens are still detectable in the tissues and serum of advanced prostate cancer patients.
“However, a paradigm shift occurred upon reports by a number of groups demonstrating that despite being surgically or chemically castrated, very low levels of androgens are still detectable in the tissues and serum of advanced patients (2,3).”
From Minireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer (2011) · cites this paper as [2]
Cited by
Sorted by citations
Efstathiou, E., Titus, M. A., Wen, S., Hoang, A. G., Κάρλου, Μ., Ashe, R., Tu, S. M., Aparicio, A. M., Troncoso, P., Mohler, J. L., et al. (2014) · European Urology · doi:10.1016/j.eururo.2014.05.005 · Cited by 245 · see citing works
“The role of tumorassociated androgen biosynthesis and its therapeutic relevance is established [1,4,6–9].”
BackgroundEffects of Abiraterone Acetate on Androgen Signaling in Castrate-Resistant Prostate Cancer in Bone
Efstathiou, E., Titus, M. A., Tsavachidou, D., Tzelepi, V., Wen, S., Hoang, A. G., Molina, A., Chieffo, N., Smith, L. A., Κάρλου, Μ., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.33.7675 · Cited by 188 · see citing works
“All patients had bone-metastatic CRPC.”
BackgroundResultInfluentialMinireview: Alternative Activation Pathways for the Androgen Receptor in Prostate Cancer
Lamont, K. R., & Tindall, D. J. (2011) · Molecular Endocrinology · doi:10.1210/me.2010-0469 · Cited by 150 · see citing works
“the tissues and serum of advanced patients (2, 3).”
BackgroundThe hallmarks of castration-resistant prostate cancers
Katsogiannou, M., Ziouziou, H., Karaki, S., Andrieu, C., de Villeneuve, M. H., & Rocchi, P. (2015) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2015.05.003 · Cited by 107 · see citing works
“Tumors that relapse CT were first thought to be ‘‘an drogen-independent’’, but very low levels of androgens may still be detectable in the tissues and serum of advanced patients [8,9].”
BackgroundAndrogen Receptor Activation by Gs Signaling in Prostate Cancer Cells
Kasbohm, E. A., Guo, R., Yowell, C. W., Bagchi, G., Kelly, P., Arora, P., Casey, P. J., & Daaka, Y. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m414423200 · Cited by 72 · see citing works
Tamae, D., Byrns, M. C., Marck, B. T., Mostaghel, E. A., Nelson, P. S., Lange, P. H., Lin, D. W., Taplin, M., Balk, S. P., Ellis, W., et al. (2013) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2013.06.014 · Cited by 51 · see citing works
The CXCL12/CXCR4 axis promotes ligand-independent activation of the androgen receptor
Kasina, S., & Macoska, J. A. (2012) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2011.12.015 · Cited by 47 · see citing works
“…conversion of androgen precursors to active androgen, or the production of active androgens by the adrenal glands, can maintain the AR in an active and functional state in the prostate under these conditions [Geller, 1995; Gregory et al., 2004; Mohler, 2008; Mohler et al., 2011; Tan et al., 1997].”
Background
- Authors
- Geller, J.
- Affiliations
- University of California San Diego (US)
- Corresponding author
- Geller, J
- Venue
- The Journal of Clinical Endocrinology & Metabolism
- Publisher
- The Endocrine Society
- Published
- 1995-04
- Volume
- 80
- Issue
- 4
- Pages
- 1074-1078
- ISSN
- 0021-972X (ISSN-L)
- 1945-7197
- OpenAlex
- W2004905634
- Cited by
- 8
- References
- 0
- Citations by year
- 2015: 1 · 2014: 1 · 2013: 2 · 2012: 1
- FWCI
- 0.00
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The Journal of Clinical Endocrinology & Metabolism (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Treatment and Research
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Hormonal and reproductive studies
- Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Prostate Cancer Diagnosis and Treatment
- Keywords
- metastatic prostate cancer, adrenal androgens, androgen deprivation therapy, survival, treatment controversies, androgen production
- MeSH terms
- Adrenal Glands, Androgen Antagonists, Androgens, Humans, Male, Neoplasm Staging, Orchiectomy, Prostatic Neoplasms, Time Factors, Survival Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
